Category Archives: Science Research Technology

Science Research Technology

Innovative mass finishing process increases the efficiency of turbines

Specially selected grinding media improve the airflow characteristics of blades.

Innovative mass finishing process increases the efficiency of turbines

The MV multivibrators are equipped with high-speed imbalance motors.

At the ALUMINIUM 2018 exhibition Walther Trowal presents its new process for the gentle surface finishing of guide vanes used in turbines and compressors. It creates very smooth surface readings and, thus, optimizes the airflow through the guide vanes.

After they have been milled from a cast block of aluminium, guide vanes for turbines or compressors require a very smooth surface to insure optimum airflow around every single blade. To date this required a complex and costly mechanical process.

Walther Trowal has recently developed a method that allows the gentle smoothing of the guide vanes after milling without rounding the leading edges beyond the acceptable tolerances – an important factor for increasing the efficiency of jet engines.

Basis for the new process are the rotary multi vibrators of the model range MV allowing the processing of guide vanes with diameters of up to 800 mm. The company utilizes special, extremely small ceramic grinding media, which provide not only optimum surface coverage on the work pieces but also smoothens the surface at the root of the vanes.

The guide vanes, but also blisks, are mounted to a fixture that is magnetically attached to the base of the processing bowl. This ensures that the overlapping, high-frequency vibrations from the multi vibrator are transferred to the work piece, causing intensive contact between the media and the vane surface areas.

The result of the fully automatic finishing process: The milling lines from the preceding machining step have been ground out creating a very smooth surface. With the new process Walther Trowal reduces the Ra surface readings from 4.0 down to 1.0 µm with only minimal rounding of the leading edges. This innovative mass finishing process creates ideal conditions for an optimum airflow through the guide vanes.

At the ALUMINIUM 2018 Walther Trowal also presents rotary vibrators used for the surface finishing of aluminium castings including the removal of burrs.

Walther Trowal at ALUMINIUM 2018
Düsseldorf, September 18 – 22, 2018
Hall 12, Stand G50

Facts about Walther Trowal

For 85 years Walther Trowal has been a pioneer and market leader in various surface treatment technologies. The company offers modular and custom engineered solutions for a wide range of surface treatment problems.

Initially only making vibratory finishing equipment, over the years Walther Trowal has continuously broadened its product range and today offers a wide portfolio of equipment and services for improving all kinds of surfaces, e.g. mass finishing, part cleaning, shot blasting and drying of a wide spectrum of work pieces, last but not least, the coating of mass produced small parts.

Walther Trowal offers not only various types of equipment but complete surface treatment systems: By linking the various equipment modules and automating the complete process, we are able to precisely adapt our process technologies to the technical requirements of our customers. This also includes various types of peripheral equipment and process water cleaning and recycling systems. Of course, we also offer comprehensive pre- and after-sale service like sample processing in one of our demonstration labs and global repair and maintenance service.

Walther Trowal serves many customers in many industries around the world. For example, in the automotive and aerospace industry, medical engineering and wind power generation.

Company-Contact
Walther Trowal GmbH & Co.KG
Georg Harnau
Rheinische Str. 35-37
42781 Haan, Germany
Phone: +49 2129.571-0
Fax: +49 2129.571-225
E-Mail: info@walther-trowal.de
Url: http://www.walther-trowal.de

Press
VIP Kommunikation
Regina Reinhardt
Dennewartstraße 25-27
52068 Aachen, Germany
Phone: +49.241.89468-24
Fax: +49.241.89468-44
E-Mail: reinhardt@vip-kommunikation.de
Url: http://www.vip-kommunikation.de

Science Research Technology

GKN Powder Metallurgy Partners with HP and Volkswagen to Bring Metal 3D Printing to Mass Production

Partnership Set to Disrupt Traditional Manufacturing, Break Design Barriers and Accelerate the Adoption of Binder Jetting Technology

GKN Powder Metallurgy Partners with HP and Volkswagen to Bring Metal 3D Printing to Mass Production

Peter Oberparleiter, CEO GKN Powder Metallurgy

Chicago, IL – September 11, 2018 – GKN Powder Metallurgy, a leading innovation development partner of the manufacturing industry, today announced a strategic collaboration with HP Inc. at the 2018 International Manufacturing Technology Show (IMTS). The company will be the first to deploy the just-launched HP Metal Jet, a groundbreaking binder jetting technology, into its factories to produce functional metal parts for auto and industrial leaders, including Volkswagen and Wilo, and for companies around the world.
Together with HP, GKN Powder Metallurgy is working toward a vision of driving the global industrialization of additive manufacturing. The HP Metal Jet launch represents a paradigm shift in 3D printing for all markets as the new printer increases users‘ productivity up to 50 fold, compared to other 3D printing methods, at nearly half the cost of other binder jetting systems. The technology will enable GKN Powder Metallurgy to transform future product thinking and traditional manufacturing on behalf of its customers by reducing the time-to-market for mass-produced parts from months to weeks, lowering development costs, and providing greater design and manufacturing flexibility.

„Our vision for additive manufacturing in the enterprise moves beyond prototypes and small-series production and into mass production. We see a future where every modern digital company will have a cutting-edge 3D printer in their facilities, enabled by GKN technology, design and support, to produce metal parts in 24 hours. This strategic partnership with HP is the tipping point to accelerate that vision,“ said Peter Oberparleiter, CEO of GKN Powder Metallurgy. „Powder production and metal part processing are part of our DNA, and we have a long history of collaborating with customers and industrializing solutions that bring great benefits to the entire industry. As we join forces with HP, we want our customers to challenge us to break design barriers and accelerate the adoption of binder jetting technology as it is a wonderful compliment to our existing Additive Manufacturing technology offerings.“

As the world’s largest producer of metal parts, GKN Powder Metallurgy is uniquely positioned to advance the development of the binder jetting industry. By integrating the HP Metal Jet into the workflow across its plants worldwide, GKN Powder Metallurgy will leverage its metal expertise to engineer new powders based on customer needs and help them design parts they did not realize were possible. The company will build on its foundation of sintering 13 million metal parts per day and continue on the path to Industry 4.0, since binder jetting is a highly digital process and GKN Powder Metallurgy has already digitized its factory floors.

„HP is proud to partner with GKN Powder Metallurgy to bring the power of 3D mass production to the largest industries on earth, such as the auto and industrial sectors,“ said Stephen Nigro, President of 3D Printing, HP Inc. „The combination of HP’s breakthrough Metal Jet technology and GKN’s engineering and manufacturing leadership, promises to enable the production of millions of high-quality, low-cost 3D-printed final parts.“

In the first half of 2019, customers will be able to receive industrial-grade parts in higher quantities. GKN will produce parts using HP Metal Jet to ensure the highest standards of engineering and production quality. GKN Powder Metallurgy will be the only partner using the HP Metal Jet within the automotive and industrial market until the machine becomes generally available in 2020. For more information about this partnership, visit https://www.gkn.com/hp. To connect with GKN Powder Metallurgy at IMTS, join them at Booth #121602.

GKN Powder Metallurgy is your full metal shapes solutions provider, shaping powder metal into high performance and high precision components. We provide leading powder metal expertise and process experience to transform ideas into production. The company consists of GKN Hoeganaes, GKN Sinter Metals, and GKN Additive to provide powder materials, conventional components, and Additive Manufacturing production. We combine three focused businesses under one brand. Together we are over 7,400 problem solvers in over 34 locations, setting our global engineering network at the highest standard.

Contact
GKN Sinter Metals Engineering GmbH
Susanne Trautmann
Krebsöge 10
42477 Radevormwald
Phone: +49 (2289) 895980
E-Mail: Susanne.Trautmann@gkn.com
Url: https://www.gkn.com/hp

Science Research Technology

API Manufacturing – Future Growth Predictions – 2021

API Manufacturing - Future Growth Predictions - 2021

Browse 369 market data tables and 46 figures spread through 312 pages and in-depth TOC on „Active Pharmaceutical Ingredients/API Market“
https://www.marketsandmarkets.com/Market-Reports/API-Market-263.html
Early buyers will receive 10% customization on this report.

The global Active Pharmaceutical Ingredients market is expected to reach USD 213.97 Billion by 2021 from USD 157.95 Billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021.

On the basis of type, the active pharmaceutical ingredients market is segmented into innovative and generic APIs. The innovative APIs segment is estimated to command the largest share in 2016.

Some of the major factors contributing to its large share include growing demand for innovative therapeutics for treatment of dreadful diseases, especially cancer, the increase in the number of FDA approvals for new molecular entities and the higher prices of innovative APIs (as compared to generics).

On the basis of type of manufacturer, the active pharmaceutical ingredients market is segmented into captive and merchant API manufacturers.

Download the PDF Brochure@
https://www.marketsandmarkets.com/pdfdownload.asp?id=263

The APIs market, on the basis of type of synthesis, is segmented into synthetic and biotech APIs. Synthetic APIs is estimated to dominate this market in 2016.The large share of this segment can be attributed to the emergence of new synthetic molecules in the market, increasing number of new product approvals, less complex manufacturing and approval processes as compared to biologics and technological advancements in the method of synthesis.

However, the biotech APIs market is expected to grow at a substantially higher rate during the forecast period owing to advances in biotechnology, growing demand for biopharmaceuticals due to their specificity in action, their similarity with the natural biological compounds, and significant growth in the demand for monoclonal antibodies.

Based on product, the biotech active pharmaceutical ingredients market is segmented into monoclonal antibodies, hormones, vaccines, cytokines, fusion proteins, therapeutic enzymes, and blood factors.

In 2015, the monoclonal antibodies segment account accounted for the largest share of the global biotech active pharmaceutical ingredients market. Growing incidence of cancer, increasing investments in R&D, technological advances in genetic sequencing and target gene selection, and increasing application of mAbs in oncology reduced side effects as compared to chemotherapy are some of the major factors responsible for the large share of monoclonal antibodies in this market.

Get the Sample Pages@
https://www.marketsandmarkets.com/requestsample.asp?id=263

Based on geography, the global active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2016. This large share can be attributed to various factors including increasing incidence of chronic diseases, increasing focus of the government on the growing adoption of generic drugs, rising demand for biologics and specialty drugs, and technological advances in API manufacturing.

Prominent players in the active pharmaceutical ingredients market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (U.S.), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.) and AbbVie Inc. (U.S.).

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies“ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the „Growth Engagement Model – GEM“. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write „Attack, avoid and defend“ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets“s flagship competitive intelligence and market research platform, „Knowledgestore“ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact
MarketsandMarkets
Makarand Vaidya
630 Dundee Road Nr.
60062 Suite 430, Northbrook
Phone: 8886006441
E-Mail: makarand.vaidya@marketsandmarkets.com
Url: https://www.marketsandmarkets.com/

Science Research Technology

World“s largest scale alkaline water electrolysis system with power of 10 Megawatt from Asahi Kasei selected for Fukushima Hydrogen Research Center

Düsseldorf, August 14, 2018 – Asahi Kasei and its subsidiary Asahi Kasei Engineering Corp. have received an order from Toshiba Energy Systems & Solutions Corp. for an alkaline water electrolysis system of the world-leading scale of 10 MW in a single unit to be installed at the Fukushima Hydrogen Research Field in Namie, Futaba, Fukushima, Japan.

The development of a large-scale alkaline water electrolysis system featuring high energy efficiency and outstanding responsiveness with fluctuating output was achieved based on Asahi Kasei“s world-leading chlor-alkali electrolysis technology. The project is being supported by Japan“s New Energy and Industrial Technology Development Organization (NEDO).

Toshiba Energy Systems & Solutions was commissioned by NEDO to implement a „Hydrogen from Renewable Energy Project“ in Namie, as a technological development project.

Integrated with a large-scale solar power generation plant, the electrolysis system will form a core part of the Fukushima Hydrogen Research Field scheduled for test operation in the autumn of 2019 and start-up in the summer of 2020.

Asahi Kasei“s alkaline water electrolysis system is an example of „power-to-gas“ technology to convert renewable energy into clean hydrogen which is expected to be widely utilized in transportation and industrial applications as a substitute for fossil fuel. The market is expected to grow significantly with the shift to a low-carbon society.

Participation in this project accords with Asahi Kasei“s medium-term strategic objective of providing solutions to society in the area of clean environmental energy.

About Asahi Kasei
Asahi Kasei Corporation is a globally active diversified technology company with operations in the Material, Homes, and Health Care business. The Material division encompasses fibers & textiles, petrochemicals, performance polymers, performance materials, consumables, battery separators, and electronic devices. The Homes division provides housing and construction materials to the Japanese market. The Health Care division includes pharmaceuticals, medical devices, and acute critical care devices and systems. With approximately 34,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.

Asahi Kasei is „Creating for Tomorrow“ with all operations sharing a common mission of contributing to life and living for people around the world. For more information, visit

www.asahi-kasei.co.jp/asahi/en/
www.asahi-kasei.eu/

If you have any queries, please address them to:

Company contact Europe
Asahi Kasei Europe GmbH
Sebastian Schmidt
Am Seestern 4
40547 Düsseldorf
Phone: +49 (0)211 280 68 139
E-mail: Sebastian.Schmidt@asahi-kasei.eu

Press contact
financial relations GmbH
Henning Küll
Louisenstraße 97
61348 Bad Homburg
Telefon: +49 (0) 6172 27159 12
Phone: +49 (0) 175 903 42 29
E-Mail: h.kuell@financial-relations.de

The Asahi Kasei Group is a diversified group of companies led by Asahi Kasei Corp., with operations in the Material, Homes, and Health Care business sectors. Asahi Kasei distributes its innovative technologies and unique materials on markets worldwide.
With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. Asahi Kasei is „Creating for Tomorrow“ with all operations sharing a common mission of contributing to life and living for people around the world.

Company-Contact
Asahi Kasei Europe GmbH
Sebastian Schmidt
Am Seestern 4
40547 Düsseldorf
Phone: +49 (0)211 280 68 139
E-Mail: Sebastian.Schmidt@asahi-kasei.eu
Url: https://www.asahi-kasei.eu/

Press
financial relations GmbH
Henning Küll
Louisenstraße 97
61348 Bad Homburg
Phone: +49 (0) 6172 27159 12
E-Mail: h.kuell@financial-relations.de
Url: http://www.financial-relations.de

Science Research Technology

Gentle finishing of extremely hard surfaces

Overlapping rotational work piece movement is the basis for even, all-around surface finishes

Gentle finishing of extremely hard surfaces

The spindles allow the processing of batches of up to 18 work pieces. For this photo different work

At this year“s IMTS Walther Trowal is introducing the new drag finisher M-TMD 6M for treating high-value components that require a first-class surface quality. The new drag machines will place a mirror polish on the hardest materials – even on ceramic components. With these machines the costs for polishing can be reduced to a fraction of the costs for manual surface grinding and polishing. But even more important: They ensure absolutely repeatable, high-quality finishing results within an extremely narrow tolerance band.

Walther Trowal developed these new machines specifically for treating high-value components requiring extremely careful handling for the complete finishing process. For example, they are utilized for finishing the surface of turbine blades, impellers for turbo chargers, precision components for pumps and compressors as well as for orthopedic implants.

The new drag machines of the M-series have a carousel with multiple rotating workstations. In turn each workstation is equipped with spindle heads containing several spindle drives onto which the work pieces are attached with special fixtures. In addition, these machines also contain a stationary work bowl filled with grinding or polishing media. As the work pieces are „dragged“ through the stationary media mass, the simultaneous rotational work piece movement by carousel, workstations and spindles creates different overlapping patterns, which ensure an even and intensive coverage of the complete work piece surface.

Christoph Cruse, director of sales at Walther Trowal, foresees a big demand for these machines at some of his customers who produce delicate, high-value components. He explains: „With our new machines we want to assist the manufacturers of work pieces that must receive the best possible surface finish, and where even the slightest surface flaw or scratch might cause them to be scrapped. Furthermore, we target parts where deviations from the dimensional specifications of a few thousands mm can be a detrimental. The M-TMD drag finishers with their perfect surface coverage open brand-new possibilities for finishing such work pieces.“

Die M-TMD 4 drag finisher is equipped with four work stations and can process 12 parts in one single batch; the M-TMD 6 – with six work stations allows batch sizes of up to 18 pieces.

At this year“s IMTS Walther Trowal also displays a range of mass finishing equipment including rotary vibrators, the MV multi vib vibrators and a high-energy centrifugal disk finishing machine.

One drag finishing success story:
Polishing of the extremely wear resistant ceramic coating on orthopedic implants

One example for the successful use of the new drag finishers is a process, specifically developed by Walther Trowal, for polishing of knee femorals made from a chromium-nickel alloy, which are covered with a ceramic coating applied with a special vapor deposit method. To date these parts had to be finished manually in time consuming multiple steps with the risk of high quality fluctuations.

After a pre-grinding step the ceramic coating is polished in the new M-TMD drag finisher with a polishing medium specifically developed for this application. The result: Although the ceramic coating is extremely hard, the drag finisher produces a very smooth, shiny and highly wear resistant finish from the initially rough surface condition. The new coating extends the fatigue life of the implants from to date about 20 up to 30 years!

In developing this process Walther Trowal took an entirely new approach. Instead of using relatively soft polishing materials the company is adding an extremely hard substance to the polishing medium, namely diamond powder.

Christoph Cruse explains the advantages of the new process as follows: „Soft materials can be polished relatively easily. But the manual polishing of extremely hard coatings has been extremely difficult, especially because an even surface finish is essential for the functionality of the component. In the case of vapor deposit coating, with a layer thickness of just a few microns, it is essential not to remove too much of the coating material from the part surface. With the M-TMD drag finishing technology and the new polishing media we have resolved this difficulty: The finish is absolutely even on the entire surface area of the implants.“

Walther Trowal at the IMTS 2018
September 10 – 15, 2018, Chicago, IL, USA
North Building, Level 3, Booth 236609

The technical details

In standard drag finishers the work pieces are directly mounted to the workstations and „dragged“ through the stationary media bed producing an extremely high processing intensity. This method is more than adequate for most work pieces and produces excellent finishing results.

The new M-TMD systems allow one additional rotational movement, namely that of the spindles mounted to the workstations. The multi-spindle heads on the workstations can be also be angled allowing the adaptation of the media coverage on the work piece surface to different work piece geometries.

All process steps, from cut-down, over surface smoothing to the final polishing, take place in the same machine, without having to remove the work pieces from the spindles.

The new drag finishers are suitable for dry as well as wet processing. In wet processes for cut-down, surface smoothing and, occasionally, for polishing, special finishing compounds are used. For the targeted edge radiusing within a tolerance range of a few thousands mm, like for example for tungsten carbide drill bits or milling tools, dry grinding media are utilized. Dry processing is also used for high gloss polishing with special pastes and polishing media.

Facts about Walther Trowal

For 85 years Walther Trowal has been a pioneer and market leader in various surface treatment technologies. The company offers modular and custom engineered solutions for a wide range of surface treatment problems.

Initially only making vibratory finishing equipment, over the years Walther Trowal has continuously broadened its product range and today offers a wide portfolio of equipment and services for improving all kinds of surfaces, e.g. mass finishing, part cleaning, shot blasting and drying of a wide spectrum of work pieces, last but not least, the coating of mass produced small parts.

Walther Trowal offers not only various types of equipment but complete surface treatment systems: By linking the various equipment modules and automating the complete process, we are able to precisely adapt our process technologies to the technical requirements of our customers. This also includes various types of peripheral equipment and process water cleaning and recycling systems. Of course, we also offer comprehensive pre- and after-sale service like sample processing in one of our demonstration labs and global repair and maintenance service.

Walther Trowal serves many customers in many industries around the world. For example, in the automotive and aerospace industry, medical engineering and wind power generation.

Walther Trowal in America

The recently opened „Tech & Training Centre“ of the Walther Trowal LLC in Grand Rapids, Michigan has, among other equipment, a test lab for the „Trowal Coating“ technology allowing interested customers informing themselves about the most suitable coating method for their work pieces.

Trowal has also extended its presence in Latin America by recently opening a sales office in Mexico, which is, of course, using the knowhow and resources of the Grand Rapids facility.

Company-Contact
Walther Trowal GmbH & Co.KG
Georg Harnau
Rheinische Str. 35-37
42781 Haan, Germany
Phone: +49 2129.571-0
Fax: +49 2129.571-225
E-Mail: info@walther-trowal.de
Url: http://www.walther-trowal.de

Press
VIP Kommunikation
Regina Reinhardt
Dennewartstraße 25-27
52068 Aachen, Germany
Phone: +49.241.89468-24
Fax: +49.241.89468-44
E-Mail: reinhardt@vip-kommunikation.de
Url: http://www.vip-kommunikation.de

Science Research Technology

Skilfully networking science and business

Science2Start winners 2018: University Hospital Tübingen, Max Planck Institute for Developmental Biology, Natural and Medical Sciences Institute at Tübingen University and Fraunhofer IGB

Skilfully networking science and business

The Science2Start award ceremony 2018 held at the BioRegio STERN summer party (Source: A. Faden/BioRegio STERN Management GmbH)

(Stuttgart/Reutlingen) – During the Science2Start award ceremony held at the BioRegio STERN 2018 summer party, four teams of scientists and entrepreneurs were honoured for their ideas, all of which boast enormous economic potential. First place was awarded to Professor Bernhard Hirt from the University Hospital Tübingen’s Institute of Clinical Anatomy and Cell Analysis for his idea of the formaldehyde substitute „aminolipin“. Second place went to a software solution for genetically analysing bacterial strains to effectively combat multiresistant bacteria. Tying in third place were two lab-on-a-chip test systems for developing medication to treat neurodegenerative and retinal diseases. The Reutlingen-based artist Jenny Winter-Stojanovic wowed a long list of guests from the worlds of science, business and politics with a spectacular live installation created with cling film in the Tübingen observatory.

Last Thursday, the 2018 winners of the tenth „Science2Start“ ideas competition were announced at this year’s joint summer reception held at the Tübingen observatory. The event was organised by BioRegio STERN Management GmbH, the Verein zur Förderung der Biotechnologie und Medizintechnik e. V. (Society for the Promotion of Biotechnology and Medical Technology) and Tübingen-Reutlingen Technology Park (TTR). In his keynote speech on leadership, Dr. Peter Heinrich – serial entrepreneur, founder of Medigene AG, and co-founder and spokesman for the Executive Board of BIO Deutschland – quoted the poet and author Antoine de Saint-Exupery: „If you want to build a ship, don’t drum up the men to gather wood, divide the work and give orders. Instead, teach them to yearn for the vast and endless sea.“ Giving some advice to the future entrepreneurs, Dr. Heinrich then said: „The trick to leadership lies, among other things, in creating an atmosphere and the necessary conditions to motivate people to work together towards goals.“

Although the four winners of the tenth ideas competition are just starting out in the world of business, the specialist panel of Science2Start judges viewed their projects as boasting great economic potential. Leading the way was Professor Bernhard Hirt from the University Hospital Tübingen’s Institute of Clinical Anatomy and Cell Analysis with his idea of the formaldehyde substitute „aminolipin“. Second place was awarded to Dr. Wei Ding and Benjamin Buchfink from the Max Planck Institute for Developmental Biology in Tübingen for their „PanX+“ software, which is designed to genetically analyse bacterial strains and thus effectively combat multiresistant bacteria. The Natural and Medical Sciences Institute (NMI) at Tübingen University and the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB) from Stuttgart tied in third place with their lab-on-a-chip test systems for developing medication. The „3D in vitro platform“ developed by Dr. Paolo Cesare targets neurodegenerative diseases, while the „retina-on-a-chip“ presented by Dr. Christopher Probst focuses on treating retinal diseases. The prize money awarded totalled 4,500 euros and, as in previous years, was donated by Voelker & Partner, a firm of lawyers, tax consultants and auditors.

At the subsequent summer reception organised by BioRegio STERN Management GmbH, numerous researchers, entrepreneurs and politicians discussed various exciting topics until late into the evening. One topic of conversation was Jenny Winter-Stojanovic – the Reutlingen-based artist gave guests a live performance, producing a sculpture with cling film that, in combination with the lighting, created a sensational membrane structure stretching from around the iron pavilion into the Tübingen observatory. Hosting the event, BioRegio STERN’s Managing Director Dr. Klaus Eichenberg was delighted to see the art installation give guests food for thought. „Entrepreneurs need to have inspiring ideas and implement them creatively if they want scientific ideas to result in success. They need good connections, too. We are able to help in this respect – by hosting this event, for example,“ said Dr. Eichenberg.

Descriptions of winning projects from the 2018 Science2Start ideas competition

1st place: „Aminolipin“ developed by Prof. Bernhard Hirt from the Institute of Clinical Anatomy and Cell Analysis at Tübingen University
The team of the Institute of Clinical Anatomy and Cell Analysis has developed the substance Aminolipin as a fixing and preservation agent for solid specimens, organs and tissue. It inhibits enzymes that are responsible for decomposition, exhibits a wide antimicrobial efficacy spectrum and is highly efficient in halting the process of putrefaction. Until now, medical professionals have used the toxic and carcinogenic substance formaldehyde to preserve biological tissue, and even entire human bodies. Corpses prepared with Aminolipin closely resemble live patients in form, colour and look and therefore help to enhance doctors‘ training.

2nd place: „PanX+“ developed by Dr. Wei Ding and Benjamin Buchfink, Max Planck Institute for Developmental Biology, Tübingen
PanX+ is an interactive software solution for analysing and visualising bacteria genomes to fight off multiresistant bacteria. Dr. Ding developed panX software to quickly evaluate and interactively visualize the pangenome – in other words, the entire gene set of bacteria strains. His team, known as PathoVis, has developed the new PanX+ software, which makes it possible to analyse enormous volumes of data in less than a day. The epidemiological data is visualised, which allows researchers to investigate the causes of bacteria and give hospitals and public health authorities recommendations on how to prevent multiresistant bacteria from spreading further.

3rd place: „3D in vitro platform“ developed by Dr. Paolo Cesare, Natural and Medical Sciences Institute (NMI) at Tübingen University
Dr. Paolo Cesare’s team has produced an innovative brain-on-a-chip platform and managed to substantially develop Cesare’s MEAFLUIT system of microelectrode arrays fitted with microfluid technology, which secured them a Science2Start award back in 2015. The test system can be used to cultivate and interconnect human neurons. In this way, the 3D in vitro platform makes it easier to develop effective medication for Alzheimer’s and Parkinson’s disease, for example, and circumvents the need for animal testing.

3rd place: „Retina-on-a-chip“ developed by Dr. Christopher Probst, Fraunhofer IGB, Stuttgart
„Retina-on-a-chip“ is an innovative 3D in vitro test system. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB) and Eberhard Karls University of Tübingen have succeeded in simulating the human retina in vitro to enable scientists to undertake more efficient pharmacological drug research for treating as yet incurable retinal diseases such as age-related macular degeneration and retinitis pigmentosa. Compared to current testing methods, the 3D retina model and the vasculature-like perfusion of nutrients gives researchers a much better insight into their object of study. The use of pluripotent stem cells as the raw material also helps to reduce the number of tests carried out on animals in pre-clinical drug research and testing.

About BioRegio STERN Management GmbH:
BioRegio STERN Management GmbH promotes economic development in the life sciences industry, helping to strengthen the region as a business location by supporting innovations and start-up companies in the public interest. It is the main point of contact for company founders and entrepreneurs in the Stuttgart and Neckar-Alb regions, including the cities of Tübingen and Reutlingen.
The STERN BioRegion is one of the largest and most successful bioregions in Germany. Its unique selling points include a mix of biotech and medtech companies that is outstanding in Germany and regional clusters in the fields of automation technology and mechanical engineering.

Company-Contact
BioRegio STERN Management GmbH
Dr. Klaus Eichenberg
Friedrichstrasse 10
70174 Stuttgart
Phone: +49 (0)711-870354-0
E-Mail: info@bioregio-stern.de
Url: http://www.bioregio-stern.de/en

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Strasse 58a
70184 Stuttgart
Phone: +49 (0)711-6070719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Optic chip with a long service life

Success for Retina Implant – retinal implant still functioning after more than 50 months

Optic chip with a long service life

The subretinal implant Alpha AMS by Retina Implant AG (Source: Retina Implant AG)

(Reutlingen) – The subretinal implant from Retina Implant AG has successfully demonstrated its long service life under real-life conditions. Implanted back in 2014, the chip is still functional and has enabled a previously completely blind RP patient, now in her 70s, to perceive light. The fact that the implant has thus exceeded a service life of over 50 months is a great technological success for the Reutlingen-based medtech company.

Retinitis pigmentosa (RP) is a degenerative retinal disease that leads to the destruction of the retina and often total blindness in the final stage. It is regarded as a „rare disease“, yet affects 20,000 to 30,000 people in Germany alone and around three million individuals worldwide. Retina Implant AG from Reutlingen has developed a subretinal implant that is able to restore partial sight to people who perceive very little or no light due to various forms of degenerative retinal diseases such as RP.

In Tübingen, an RP patient who had already lost all her sight received the implant in 2014. The chip implanted in the patient, now in her 70s, has been in operation for more than four years – and still functions as it did in the beginning. For instance, the patient can identify light sources and therefore find her way around more easily. „One of the greatest challenges when developing the implant was ensuring the camera chip in the eye would remain functional over many years,“ explains Dr. Alfred Stett, CTO of Retina Implant AG. „Unlike pacemakers and neurostimulators, which have their electronics and battery packaged in a fixed, hermetically sealed casing, our electronic chip is in direct contact with the retina – a light-permeable barrier layer that is a few micrometres thick is the only form of protection.“

The subretinal implant features 1,600 photodiodes and stimulation contacts that partially replace photoreceptors destroyed by RP. The chip is only around 12 square millimetres in size and is placed directly below the fovea centralis, which means it can move with the eye to locate objects. The latest generation of the implant, known as the RETINA IMPLANT Alpha AMS, was awarded CE certification back in 2016. In Germany, the cost of the implant is reimbursed by the statutory health insurance providers.

„Our forecasts regarding shelf life were previously based on ageing tests conducted in the laboratory and on model-based estimates of service life that are commonplace in the aviation industry, for example. These tests and estimates predicted a service life of 4.7 years. Our patient’s experience shows that we are on the right path. This success is the result of 15 years of intensive research and development to give blind people fresh hope,“ says Dr. Stett.

Dates
25 August 2018 Patient information day for congenital retinal diseases at Knappschaftsklinikum Saar GmbH, An der Klinik 10, 66280, Sulzbach, Germany, Augenklinik Sulzbach (Sulzbach Eye Hospital).

About Retina Implant AG
Retina Implant AG researches and develops innovative treatments and high-tech products for people suffering from retinitis pigmentosa (RP). The subretinal RETINA IMPLANT Alpha AMS can help blind patients regain a certain degree of useful sight. The CE-approved microchip is implanted beneath the retina (subretinally) at specialist RI implantation centres.
Transcorneal electrical stimulation (TES treatment) with the RI OkuStim® system offers RP patients with sufficient residual vision the opportunity to slow down the progression of the disease.
The company, based in Reutlingen, employs around 45 people and is managed by Reinhard Rubow (CEO and speaker of the Management Board), Jürgen Klein (Member of the Board, Sales & Marketing) and Dr. Alfred Stett (CTO, Member of the Board).

Company-Contact
Retina Implant AG
Volker Hiller
Gerhard-Kindler-Str. 13
72770 Reutlingen
Phone: + 49 71 21 3 64 03 – 282
E-Mail: volker.hiller@retina-implant.de
Url: https://www.retina-implant.de/en/

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
Phone: 0711-60 70 719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

CeramOptec: Holger Bäuerle appointed Vice Managing Director

The experienced sales manager will also remain head of the sales department.

CeramOptec: Holger Bäuerle appointed Vice Managing Director

Holger Bäuerle, Vice Managing Director (Source: @CeramOptec GmbH)

Bonn, July 10, 2018 – CeramOptec GmbH one of the world-leading specialists in multimode, quartz glass optical fibers, has expanded its top management: Holger Bäuerle, age 51, has been promoted to Vice Managing Director and will now act as proxy for managing directors Dr. Roland Dreschau and Dr. Damian Plange, as of July 01, 2018. The experienced sales manager joins the company since February 2015 and currently holds the position as CeramOptec’s head of industrial sales. Prior to being with CeramOptec, he was sales manager with a manufacturer of LWL-connectors for many years.

Besides his new role as vice managing director, Mr. Bäuerle will maintain leadership of the Industrial Sales Department of the optical fiber specialist at Bonn. In this position, he has been crucial for the success of the company in the field of industrial and medical laser applications in recent years. In this context, he was also deeply involved in the introduction of several of CeramOptec’s key products, e.g. the Optran© UV NCC-Fibers and the Optran© UV NSS-Fibers. In addition, Mr. Bäuerle strongly promoted the business sector of customized optical fiber products according to client specifications.

„Due to his experience as a sales manager and extensive expert knowledge of the optical fiber industry, Holger Bäuerle has advanced our company decisively and opened new market segments in recent years,“ emphasizes Dr. Roland Dreschau, CeramOptec’s Managing Director. „We are very glad being able to count on his knowledge and experience, even on the highest level of our company, while he still will be focusing on target marketing areas as our sales manager.“

About CeramOptec
CeramOptec®, in cooperation with Ceram Optec SIA, specializes in the manufacture of silica-glass multi-mode optical fibers. The medium-sized company was founded in 1988 and today is a subsidiary of biolitec AG, one of the world’s leading medical technology companies in the field of laser applications. With offices in China and distribution partners in the US, India, Japan and Korea, CeramOptec enjoys a strong presence, not only in Europe, but also in the Asian and North American markets. The range of products includes fibers, fiber bundles, assemblies and cables for a wide range of applications, including industrial and medical laser applications, aerospace sensor systems, and spectroscopic applications for use in astronomy and in the chemical industry. A specialty is the production of fiber optic cores with four- to octagonal geometry (non-circular core fibers/NCC), which are mainly used in astrophysics. The biolitec group has a total of about 245 employees.

Company-Contact
CeramOptec GmbH
Holger Bäuerle
Brühler Straße 30
53119 Bonn
Phone: +49 (0) 228 / 97 967 – 12
Fax: +49 (0) 228 / 97 967 – 99
E-Mail: holger.baeuerle@ceramoptec.com
Url: http://www.ceramoptec.com

Press
fr financial relations gmbh
Jörn Gleisner
Louisenstraße 97
61348 Bad Homburg
Phone: +49 (0) 61 72 / 27 15 9 – 0
E-Mail: j.gleisner@financial-relations.de
Url: http://www.financial-relations.de

Science Research Technology

Ideas brought to life in Anatomy

Incisions and insights workshop series – „Heart, lungs, thorax“

Ideas brought to life in Anatomy

Workshop „Incisions and insights“ at the Institute of Clinical Anatomy and Cell Analysis (Source: M. Latz/BioRegio STERN Management GmbH)

(Stuttgart/Tübingen) – The „Incisions and insights – medtech engineers and medical practitioners in dialogue“ workshop series continued in June 2018, focusing on the heart, lungs and thorax. BioRegio STERN Management GmbH is organising this exceptional series of events in collaboration with the Inter-University Center for Medical Technologies Stuttgart-Tübingen (IZST) and the Verein zur Förderung der Biotechnologie und Medizintechnik e. V. (Society for the Promotion of Biotechnology and Medical Technology). This fourth event once again saw medical directors and senior consultants meet with medtech engineers directly at operating tables in Anatomy to discuss the innovations they desire and need.

The specialists from University Hospital Tübingen have already dubbed the series of events „Make a wish“, as it gives them the opportunity to express their wishes to medtech engineers for new or improved instruments and equipment unfiltered by purchasing or marketing departments. The fourth workshop in the series focused on the heart, lungs and thorax. Alongside the live streaming of surgery and practical exercises in the operating theatre at the Institute of Clinical Anatomy and Cell Analysis, the medical directors and senior consultants from University Hospital Tübingen Dr. Helene Häberle, Senior Consultant Surgeon at the Intensive Care Unit, Prof. Alfred Königsrainer, Medical Director of General, Visceral and Transplant Surgery, Prof. Christian Schlensak, Medical Director of Thoracic and Cardiovascular Surgery, and Prof. Roland Syha, Head of Interventional Radiology, discussed potential innovations. During this session, Prof. Peter P. Pott, Head of the Institute of Medical Device Technology at the University of Stuttgart, explained what is technically feasible. Prof. Arnulf Stenzl, Medical Director of the University Department of Urology and Head of the Inter-University Center for Medical Technologies Stuttgart-Tübingen (IZST), co-chaired the workshop together with the host Prof. Bernhard Hirt, Director of the Institute of Clinical Anatomy and Cell Analysis. Around 40 medtech company representatives attended the event, which offered them an impressive range of incisions and insights.

A surgeon got straight to work on artificial heart implantation and minimally invasive lung and oesophagus surgery on an anatomical specimen. While feeding a tube into the trachea, he explained to the medtech engineers – and to medical students linked via live stream – why a second working channel would be useful: „A further piece of equipment, such as forceps, often needs to be inserted. This may also result in bleeding, which blocks the one channel.“ During the subsequent demonstration of a minimally invasive lobectomy – the removal of an organ lobe – the operating team explained the need for a second camera in order to monitor inside the thorax from an additional angle. A stapler that can attach staples and bend 90 degrees was also added to the wish list, as was a cleaning function for the camera lens. However, the surgeons‘ discussion with Prof. Pott quickly revealed that much of what is technically feasible is not at all practicable in everyday surgery. „Extra functions require cables and switches. Yet at the same time, the equipment is expected to become increasingly smaller and easier to handle.“ Physical limitations also curb miniaturisation: „A camera lens can only be reduced in size to a certain extent, otherwise it no longer transmits anything,“ explained Prof. Pott.

The subsequent artificial heart transplant once again showed that the surgeons attach great importance to small and agile instruments to open up the chest as little as possible, as this is often associated with major discomfort for patients. To implant the 200-gramme artificial heart, just two incisions are needed. Unfortunately, one of these remains permanently open, as the control and battery power cables need to be fed outside. „Of course there’s already the option of a cable-free power supply for hearing aids, for example,“ said Prof. Pott. „If this fails, the patient no longer hears anything. But if this fails in the case of the heart, the patient expires.“

The demand for innovation is therefore high, giving developers and users plenty to discuss, and this is unlikely to be exhausted at the next event in February 2019, which will focus on „Extremities and the musculoskeletal system“. „As far as we know, there’s no comparable event anywhere else in the world,“ explained Dr. Klaus Eichenberg, co-organiser and Managing Director of BioRegio STERN Management GmbH. „Surgeons are calling for new processes and instruments. I’m confident the local medtech businesses will take up this challenge and bring to life some of the ideas that were first formulated here.“

About BioRegio STERN Management GmbH:
BioRegio STERN Management GmbH promotes economic development in the life sciences industry, helping to strengthen the region as a business location by supporting innovations and start-up companies in the public interest. It is the main point of contact for company founders and entrepreneurs in the Stuttgart and Neckar-Alb regions, including the cities of Tübingen and Reutlingen.
The STERN BioRegion is one of the largest and most successful bioregions in Germany. Its unique selling points include a mix of biotech and medtech companies that is outstanding in Germany and regional clusters in the fields of automation technology and mechanical engineering.

Company-Contact
BioRegio STERN Management GmbH
Dr. Klaus Eichenberg
Friedrichstrasse 10
70174 Stuttgart
Phone: +49 (0)711-870354-0
E-Mail: info@bioregio-stern.de
Url: http://www.bioregio-stern.de/en

Press
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Strasse 58a
70184 Stuttgart
Phone: +49 (0)711-6070719
E-Mail: info@zeeb.info
Url: http://www.zeeb-kommunikation.de

Science Research Technology

Asahi Kasei Medical: New Strategies for blood purification

Asahi Kasei Medical: New Strategies for blood purification

Asahi Kasei Medical Rheofilter (Source: @Asahi Kasei)

Düsseldorf, July 5, 2018 – On May 26, Asahi Kasei Medical, a leading manufacturer of products for hemodialysis and therapeutic apheresis treatment launched the first Apheresis Meeting Industry Symposium within the Industry Symposium program of the 55th ERA-EDTA Congress in Copenhagen. 500 participants joined the Symposium.

Therapeutic apheresis is used to treat a wide range of intractable diseases, such as autoimmune diseases including rheumatoid arthritis, peripheral arterial disease, ulcerative colitis, neurological diseases or lipid disorders. Asahi Kasei Medical, founded in 1974 and the first company to globally introduce the hollow fiber separation technology, is offering therapeutic apheresis products that use membrane separation and selective adsorption technology to enable the treatment of many intractable diseases that cannot be treated using drugs. Therapeutic apheresis is increasingly used in the field of preventive medicine.

The membrane used in hollow fiber separation technology only permits plasma and proteins to pass through. Cellular components such as erythrocytes, leukocytes and thrombocytes are filtered out through the fine pores of the special hollow fibre membrane. Plasma and pathogenic substances can be removed, the plasma can be purified and returned to the patient.

During the Apheresis Meeting Industry Symposium, Professor Antonio Santoro (Bologna, Italy) chaired three sessions on Therapeutic Apheresis respectively held by Professor Lionel Rostaing (Grenoble, France), Dr. Alfonso Ramunni (Bari, Italy) and Professor Christoph Wanner (Würzburg University, Germany).

The first session by Professor Christoph Wanner titled „Lipid Apheresis and PCSK9-Antibodies:
Complementary or Competitive?“ explained how high plasma Lipoprotein(a) levels are related with the risk of myocardial infarction in the general population and which preventive action the apheresis treatment exerts by removing Lipoprotein(a) from patient“s blood.

The second session, „Rheopheresis in peripheral artery disease“ presented by Dr. Alfonso Ramunni, focused on removal of Fibrinogen from patient“s plasma and how it impacts peripheral vascular diseases such as Ischemic Diabetic Foot, Critical Limb Ischemia, Sudden Hearing Loss or Age-Related Macular Degeneration.

The third and last session, held by Professor Lionel Rostaing, „Desensitization in ABO incompatible kidney transplant candidates in order to achieve long term outcome“ explained about apheresis treatment efficiency with graft survival in ABO incompatible patients.

ERA-EDTA (European Renal Association – European Dialysis and Transplant Association), founded in 1963 aims at fostering the advancement of science and clinical work in nephrology, dialysis, renal transplantation, hypertension and related diseases with a strong focus on bettering patient“s health. It counts 7, 253 members.

ERA-EDTA Congress is the International annual scientific event that gathers about seven thousand physicians from Europe and worldwide. This year“s Congress took place in Copenhagen on 24-27 May 2018.

Asahi Kasei Medical
Asahi Kasei Medical is one of the worldwide leading manufacturers of products for hemodialysis and therapeutic apheresis treatment. The company was founded in 1974 as part of the Asahi Kasei Group which employs 35,000 employees worldwide. Asahi Kasei Medical started its activity by producing and selling unique world leading dialyzers. In 1981, the company developed and started to sell filters for therapeutic apheresis and expanded treatment options to contribute to patient“s quality of life. Asahi Kasei Medical has expanded its network worldwide by establishing subsidiaries in Europe, Asia, America and today has about 2,200 employees worldwide.

About Asahi Kasei
Asahi Kasei Corporation is a globally active diversified technology company with operations in the Material, Homes, and Health Care business. The Material division encompasses fibers & textiles, petrochemicals, performance polymers, performance materials, consumables, battery separators, and electronic devices. The Homes division provides housing and construction materials to the Japanese market. The Health Care division includes pharmaceuticals, medical devices, and acute critical care devices and systems. With approximately 35,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.

Asahi Kasei is „Creating for Tomorrow“ with all operations sharing a common mission of contributing to life and living for people around the world. For more information, visit
www.asahi-kasei.co.jp/asahi/en/
www.asahi-kasei.eu/

The Asahi Kasei Group is a diversified group of companies led by Asahi Kasei Corp., with operations in the Material, Homes, and Health Care business sectors. Asahi Kasei distributes its innovative technologies and unique materials on markets worldwide.
With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. Asahi Kasei is „Creating for Tomorrow“ with all operations sharing a common mission of contributing to life and living for people around the world.

Company-Contact
Asahi Kasei Europe GmbH
Sebastian Schmidt
Am Seestern 4
40547 Düsseldorf
Phone: +49 (0)211 280 68 139
E-Mail: Sebastian.Schmidt@asahi-kasei.eu
Url: https://www.asahi-kasei.eu/

Press
financial relations GmbH
Henning Küll
Louisenstraße 97
61348 Bad Homburg
Phone: +49 (0) 6172 27159 12
E-Mail: h.kuell@financial-relations.de
Url: http://www.financial-relations.de